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Abstract
Background: Rheumatoid arthritis (RA) is associated with an increased risk of morbidity and mortality, when
compared with general population, largely due to enhanced atherosclerotic disease. In this work, we aimed at
assessing both occurrence and predictive factors of subclinical and clinical atherosclerosis in RA.
Methods: From January 1, 2015, to December 31, 2015, consecutive participants with RA, admitted to Italian
Rheumatology Units, were assessed in the GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale)
cohort. After that, those participants were followed up in a 3-year, prospective, observational study, assessing the
occurrence of subclinical and clinical atherosclerosis and possible predictive factors. McNemar test was employed to
assess the changes in subclinical and clinical atherosclerosis, and regression analyses exploited the ORs for the
occurrence of those comorbidities.
Results: We analysed 841 participants, mostly female (82.2%) and with median age of 60 years (range 21–90). The
remission was achieved and maintained by 41.8% of participants during the follow-up. We observed an increased
rate of subclinical atherosclerosis at the end of follow-up (139 vs 203 participants, p < 0.0001), particularly in
participants with a disease duration less than 5 years at baseline (70 participants vs 133 participants, p < 0.0001).
Type 2 diabetes (T2D) (OR 4.50, 95%CI 1.74–11.62, p = 0.002), high blood pressure (OR 2.03, 95%CI 1.04–4.14, p =
0.042), ACPA (OR 2.36, 95%CI 1.19–4.69, p = 0.014) and mean values of CRP during the follow-up (OR 1.07, 95%CI
1.03–1.14, p = 0.040) were significantly associated with higher risk of subclinical atherosclerosis. We observed an
increased rate of clinical atherosclerosis at the end of follow-up (48 vs 76 participants, p < 0.0001). T2D (OR 6.21,
95%CI 2.19–17.71, p = 0.001) was associated with a significant risk of clinical atherosclerosis. The achievement and
the maintenance of remission reduced the risk of subclinical (OR 0.25, 95%CI 0.11–0.56, p = 0.001) and clinical
atherosclerosis (OR 0.20, 95%CI 0.09–0.95, p = 0.041).
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Conclusions: We reported an increased prevalence and incidence of both subclinical and clinical atherosclerosis in
3-year prospectively followed participants, mainly in the subset with a duration of disease less than 5 years. The
achievement and the maintenance of remission are associated with a reduction of the risk of subclinical and clinical
atherosclerosis. Among “traditional” cardiovascular risk factors, participants with T2D showed a higher risk of clinical
and subclinical atherosclerosis.
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Background
Rheumatoid arthritis (RA) is a systemic, inflammatory dis-
ease leading to joint damage and to a reduction of quality
of life [1, 2]. RA is associated with an increased risk of mor-
bidity and mortality, when compared with general popula-
tion, largely due to enhanced atherosclerotic disease [3, 4].
Despite the improved long-term joint damage by treatment
with synthetic and biologic disease-modifying anti-rheum-
atic drugs (DMARDs) [5–7], the close relationship between
RA and cardiovascular (CV) events has been reported, in-
cluding myocardial infarction, cerebrovascular accident and
congestive heart failure [8, 9]. Furthermore, the prevalence
of subclinical atherosclerosis is increased in RA, as shown
by studies assessing the rate of carotid artery plaques [10,
11]. Subclinical atherosclerosis may additionally identify
those patients with a higher risk to develop CV events [12].
On these bases, multiple lines of research are focused on
the development of subclinical and clinical atherosclerosis
in RA [13, 14]. This typical clinical phenotype could result
from the synergy between the elevated prevalence of “trad-
itional” cardiovascular (CV) risk factors and inflammation
[15]. In fact, although the European League Against
Rheumatism (EULAR) provided recommendations for the
management of CV risk in inflammatory arthritis [16], trad-
itional CV risk factors remain to be underdiagnosed and
undertreated in RA, thus contributing to the development
of atherosclerotic disease [17]. Concerning the rheumatoid
inflammatory process, abundant evidence strongly supports
the hypothesis that inflammation could contribute to the
pathogenesis of atherosclerotic disease beyond the elevated
traditional CV risk factors [18, 19]. Some well-known
pathogenic pro-inflammatory RA mediators could play a
pivotal role in the development of atherosclerosis, as sug-
gested by both pre-clinical and clinical reports [20, 21]. In
this context, it must be pointed out that the evidence deriv-
ing from randomised clinical trials does not entirely clarify
this issue. In fact, given strict enrolment criteria, the partici-
pants, who are usually enrolled, could not fully mirror the
real-life scenario, thus decreasing the generalisability of the
results [22]. Furthermore, the evaluation of CV burden is
mainly obtained from low-quality studies, generally with a
retrospective design and affected by different biases impair-
ing both interpretation and generalisation of results. In fact,
few prospective studies in this setting have been planned
and performed so far. Finally, a comprehensive evaluation
of CV burden in the RA could be complex as well as time-
consuming, and thus, the identification of biomarkers, ac-
curately reflecting this issue, is still awaited [15, 16, 19, 20,
23].
In this work, we aimed at evaluating both the oc-
currence and the predictive factors of subclinical and
clinical atherosclerosis in participants with RA, in a
3-year, multicentre, prospective, observational study.
Methods
Study design
From January 1, 2015, to December 31, 2015, consecutive
participants with RA, admitted to Italian Rheumatology
Units, were assessed in the GIRRCS (Gruppo Italiano di
Ricerca in Reumatologia Clinica e Sperimentale) cohort
[24]. After that, those participants were followed up in a 3-
year, prospective, observational study, assessing the occur-
rence of subclinical and clinical atherosclerosis and possible
predictive factors. The local Ethics Committee (Comitato
Etico Azienda Sanitaria Locale 1 Avezzano/Sulmona/
L’Aquila, L’Aquila, Italy; protocol number 000331/17) ap-
proved the study, which was performed according to the
Good Clinical Practice guidelines and the Declaration of
Helsinki. Informed consent was obtained from each partici-
pant for the use of clinical and laboratory data for purposes
of the study. In reporting the results, we followed the
STROBE checklist (Additional file 1: Table S1).
Setting
Participants were selected among those attending
Rheumatologic Units of GIRRCS, throughout Italy. All
the units were characterised by experience in manage-
ment of RA as well as in observational studies and by
high-volume outpatient clinics. Data of participants,
who were followed up at least for 3 years, were re-
corded during the scheduled visits, at baseline, after
12 and 36 months.
Participants
Participants fulfilling the ACR/EULAR criteria for RA
[25, 26] were included in the study.
Ruscitti et al. Arthritis Research & Therapy          (2019) 21:204 Page 2 of 10
Variables to be assessed
The main outcome of the study was the occurrence
of subclinical and clinical atherosclerosis in partici-
pants with RA, at the end of 3-year prospective fol-
low-up. Subclinical atherosclerosis was defined as the
presence of carotid and/or peripheral arteries athero-
sclerotic lesions detected by ultrasound imaging [27].
Clinical atherosclerosis was defined as the presence of
one of the following: myocardial infarction, congestive
heart failure, cerebrovascular disease including transi-
tory ischemic attack and/or stroke and clinically rele-
vant peripheral artery disease. The investigators
verified history and occurrence of clinical atheroscler-
osis by review of clinical charts, interview and med-
ical examinations of participants. Following the recent
recommendations, about CV disease (CVD) risk as-
sessment to be performed at least once every 5 years
[16], we stratified the participants in < 5 and > 5 years
of disease duration assessing the main outcomes ac-
cordingly. Additionally, by using the JBS3 calculator
[28], the 10-year CVD risk was estimated and strati-
fied in 5 categories of risk, < 10% of 10-year CVD
risk, > 10% < 20% of 10-year CVD risk, > 20% < 30%
of 10-year CVD risk, > 30% < 40% of 10-year CVD
risk and > 40% of 10-year CVD risk. Furthermore,
predictive factors of these comorbidities were assessed
by evaluating two main areas of CV risk factors,
namely the traditional and the “RA-related” ones.
Among traditional CV risk factors, we assessed gen-
der, age, smoking habit, body mass index (BMI), high
cholesterol, metabolic syndrome (MetS), type 2 dia-
betes (T2D) and high blood pressure (HBP). BMI was
calculated according to the standard formula weight
(kg)/height (m)2. High cholesterol was defined as
cholesterol > 240 mg/dl and/or treatment with medi-
cations lowering the blood cholesterol levels. MetS,
T2D and HBP were defined according to standard
criteria and/or treatment with anti-diabetic and/or
anti-hypertensive medications [29–31]. Among RA-re-
lated risk factors, we assessed the presence of
rheumatoid factor (RF) or anti-citrullinated peptide
antibodies (ACPA), disease duration, extra-articular
features, values of erythrocyte sedimentation rate
(ESR, mm/h) and C-reactive protein (CRP), radio-
graphic damage, joint surgery, disease activity and re-
mission. Disease duration was assessed from the first
disease symptom at the study beginning. Extra-articu-
lar features were defined as reported in previous
study [32]. Radiographic damage was defined as the
presence of at least one marginal erosion on previ-
ously performed hand radiography. Disease Activity
Score including 28 joints (DAS28-ESR) was used to
assess the disease activity and the remission state
(DAS28-ESR < 2.6), as previously defined [33]. ESR
was included in the assessment of DAS28 in order to
maintain the independence of CRP, a well-established
CV risk factor in the general population, for purpose
of data analysis. Participants in remission were de-
fined as those reaching after 12 months and maintain-
ing after 36 months a value of DAS28-ESR < 2.6.
We recorded the administered therapeutic strategies
during the follow-up. For those participants who under-
went sequential treatment with synthetic or biologic
DMARDs, we assigned the treatment category according
to the medication to which the participant was exposed
for a longer period. Corticosteroids (CCSs) treatment
was codified in categories, high dosage and low dosage,
as previously identified [34]. We defined participants
treated with high dosage of CCSs as those taking > 7.5
mg prednisone-equivalent for 3 months or more during
the observation period, whereas participants treated with
low dosage of CCSs as those taking ≤ 7.5 mg prednisone-
equivalent. We also recorded the use of aspirin (ASA)
during the follow-up.
Data sources
Relevant data were collected at study beginning and
reassessed after 12 and 36months, during the scheduled
visits for each involved participant by an extensive clin-
ical history.
Bias
Considering the observational design, our study could be
subjected to a number of possible biases. We tried to
minimise the main methodological problems by a careful
definition of each variable to be assessed. Furthermore,
participants with significant missing data, which were
considered to be meaningful for the analyses, were re-
moved. Specifically, participants with one or more miss-
ing data in the main outcomes were removed from the
analyses.
Study size
We would provide a “real-life” estimation of the occur-
rence of subclinical and clinical atherosclerosis in con-
secutive participants with RA in Italian Rheumatology
Units. From January 1, 2015, to December 31, 2015, con-
secutive participants with RA, admitted to Italian
Rheumatology Units, were assessed and followed up in a
3-year, prospective, observational study.
Statistical methods
Statistics firstly provided descriptive analysis of the data.
Normally distributed continuous variables were
expressed as mean ± standard deviation (SD), otherwise
as median and range interquartile, as appropriate.
McNemar test was employed to assess the changes in
subclinical and clinical atherosclerosis comparing the
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beginning and the end of follow-up and different subsets
of participants. Incident cases were reported as incidence
proportion and incidence rate per 1000 person-years at
risk. Regression analyses exploited the ORs for the oc-
currence of those comorbidities, considering data at 36
months. The purposeful selection process of covariates
started by a univariate analysis of each variable; any vari-
able having a significant univariate test was selected as a
possible candidate for the multivariate analyses. Con-
versely, covariates were removed from the models if
non-significant. At the end of this process of deleting
and refitting, the multivariate models were built and OR
estimations of significant associations with subclinical
and clinical atherosclerosis were provided. Multicolli-
nearity was evaluated by using the variance inflation fac-
tor (VIF) before entering each variable in regression
models. Participants characterised by missing data in
main outcomes were excluded from the analysis. Two-
sided P values < 0.05 were considered statistically signifi-
cant. The Statistics Package for Social Sciences (SPSS for
Windows, version 17.0, SPSS Inc., Chicago, IL, USA)
was used for all analyses.
Results
Participants and descriptive data
After assessment of 886 participants, 841 participants
with 3 years of prospective follow-up were analysed. In
the present evaluation, only participants fully followed
up for 3 years were assessed, follow-up at 12 and 36
months was performed in all these participants. The par-
ticipants, who were excluded, were characterised by
missing data in main outcomes. Baseline characteristics
of participants are described elsewhere [24]. Briefly,
assessed participants were mostly female (82.2%), me-
dian age of 60 years (range 21–90), median disease dur-
ation of 8.20 years (range 0.1–35), 73.1% displayed the
positivity for RF and/or for ACPA. During the follow-up,
72.8% of the participants were treated with CCSs (mainly
at low dosage, 60.0% of participants), 85.1% with metho-
trexate (MTX), and 61.5% with biologic DMARDs. Con-
cerning the clinical response, we observed that 41.8% of
participants reached and maintained the remission dur-
ing the follow-up. Regarding traditional CV risk factors,
31.6% of the participants reported smoking habit, 49.3%
were affected by HBP, 32.1% by high levels of choles-
terol, 22.3% by MetS and 12.1% by T2D, as shown in
Table 1.
Occurrence of subclinical atherosclerosis
We recorded that 24.1% [21.3–26.7] of participants were
defined as having subclinical atherosclerosis at the end
of follow-up, an increased rate when compared with the
beginning of the study (139 participants vs 203 partici-
pants, p < 0.0001). All participants included in the
present evaluation underwent ultrasound of peripheral
arteries, which was performed at baseline, after 12 and
36months. Analysing the incident cases of subclinical
atherosclerosis, we estimated an incidence proportion of
10.1% [8.0–12.0] and, considering over 2010 person-
years, an incidence rate of 31.8 × 1000 [24.8–38.8] per-
son-years. Furthermore, we analysed these results ac-
cording to the duration of the disease, stratifying the
participants based on duration of disease < 5 years or
duration of disease > 5 years (Fig. 1). In participants with
duration of disease < 5 years, we recorded an increased
rate of subclinical atherosclerosis when compared with
participants with duration of disease > 5 years (70 partic-
ipants vs 133 participants, p < 0.0001). Analysing the in-
cident cases of subclinical atherosclerosis in these
subsets, we estimated an incidence proportion of 20.7%
[18.1–23.3] and, considering over 610 person-years, an
incidence rate of 77.1 × 1000 person-years [56.6–97.6] in
participants with duration of disease < 5 years. Con-
versely, in participants with duration of disease > 5 years,
we estimated an incidence proportion of 5.6% [3.4–7.8]
and, considering over 1149 person-years, an incidence
rate of 19.1 × 1000 person-years [8.4–29.8] in partici-
pants with duration of disease > 5 years.
Predictive factors of subclinical atherosclerosis
A logistic regression model was built in 697 partici-
pants to evaluate the possible predictive role of se-
lected variables (age, male gender, HBP, T2D, ACPA,
mean values of CRP during the follow-up, remission)
on the likelihood of having subclinical atherosclerosis,
after 36 months. The participants, who were excluded,
were characterised by baseline evidence of subclinical
and/or clinical atherosclerosis. The analysis showed
that T2D, HBP, ACPA, remission and mean values of
CRP during the follow-up were independently associ-
ated with subclinical atherosclerosis. Participants with
comorbid T2D (OR 4.50, 95%CI 1.74–11.62, p =
0.002) and with comorbid HBP (OR 2.03, 95%CI
1.04–4.14, p = 0.042) were significantly associated with
a higher risk of having subclinical atherosclerosis. The
presence of ACPA (OR 2.36, 95%CI 1.19–4.69, p =
0.014) and mean values of CRP during the follow-up
(OR 1.07, 95%CI 1.03–1.14, p = 0.040) were also sig-
nificantly associated with a higher risk of that comor-
bidity. Of interest, the participants reaching and
maintaining remission were significantly associated
with a reduced risk of having subclinical atheroscler-
osis (OR 0.25, 95%CI 0.11–0.56, p = 0.001), as shown
in Table 2. The logistic regression model was statisti-
cally significant (χ2 = 13.09, p < 0.0001). Regarding the
possible predictive role of treatment on subclinical
atherosclerosis, we did not retrieve any significant re-
sult concerning the possible predictive role of ASA,
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MTX, HCQ, low dosage CCSs, high dosage CCSs,
TNFi and non-TNFi.
Occurrence of clinical atherosclerosis
We observed that 9.0% [8.8–9.2] of participants were
defined as having clinical atherosclerosis at the end of
the follow-up, an increased rate when compared with
the beginning of the study (48 participants vs 76 par-
ticipants, p < 0.0001). Analysing the incident cases of
clinical atherosclerosis, we estimated an incidence
proportion of 3.6% [2.4–4.8] and, considering over
2337 person-years, an incidence rate of 12.0 × 1000
person-years [8.0–16.0]. Furthermore, we analysed
these results according to the duration of the disease,
stratifying the participants based on duration of dis-
ease < 5 years or duration of disease > 5 years (Fig. 1).
In participants with duration of disease < 5 years, we
recorded an increased rate of clinical atherosclerosis
when compared with participants with duration of
disease > 5 years (27 participants vs 49 participants,
p < 0.0001). Analysing the incident cases of clinical
atherosclerosis in these subsets, we estimated an inci-
dence proportion of 19.5% [14.8–24.1] and, consider-
ing over 832 person-years, an incidence rate of 32.4 ×
1000 person-years [20.4–44.4] in participants with
duration of disease < 5 years. Conversely, in partici-
pants with duration of disease > 5 years, we estimated
an incidence proportion of 0.5% [0.2–0.8] and, con-
sidering over 1248 person-years, an incidence rate of
1.6 × 1000 person-years [0.6–3.8] in participants with
duration of disease > 5 years.
In 697 participants without baseline evidence of
subclinical and clinical atherosclerosis, the 10-year
CVD risk was estimated. We retrieved that 267 par-
ticipants (38.4%) displayed < 10% of 10-year CVD risk,
249 (40.0%) < 10% < 20% of 10-year CVD risk, 86
(12.3%) > 20% < 30% of 10-year CVD risk, 43 (6.2%)
> 30% < 40% of 10-year CVD risk and 22 (3.1%) >
40% of 10-year CVD risk.
Predictive factors of clinical atherosclerosis
A logistic regression model was built in 697 participants
to evaluate the possible predictive role of selected variables
(age, male gender, HBP, T2D, remission) on the likelihood
of having clinical atherosclerosis. The participants, who
were excluded, were characterised by baseline evidence of
subclinical and/or clinical atherosclerosis. The analysis
showed that T2D and remission were independently asso-
ciated with subclinical atherosclerosis. Participants with
comorbid T2D (OR 6.21, 95%CI 2.19–17.71, p = 0.001)
were associated with a higher risk of having clinical ath-
erosclerosis. Conversely, the participants reaching and
maintaining remission were associated with a reduced risk
of clinical atherosclerosis (OR 0.20, 95%CI 0.09–0.95, p =
0.041), as shown in Table 3. The logistic regression model
was statistically significant (χ2 = 6.37, p = 0.012). As re-
ported for subclinical atherosclerosis, we did not retrieve
any significant result concerning the possible predictive
role of ASA, MTX, HCQ, low dosage CCSs, high dosage
CCSs, TNFi and non-TNFi on clinical atherosclerosis.
Table 1 Descriptive statistics
Clinical variables
Participants, number 841
Demographic characteristics
Age (841 participants), median (range) 60 years (21–90)
Female gender (841 participants), n (%) 691 (82.2%)
RA-related features
RF and/or ACPA (841 participants), n (%) 615 (73.1%)
Disease duration (834 participants), median (range) 8.2 years (0.1–35)
Extra-articular features (840 participants), n (%) 138 (16.4%)
Radiographic damage (814 participants), n (%) 383 (47.1%)
Joint surgery (841 participants), n (%) 101 (12.4%)
Maintenance of remission (836 participants), n (%) 349 (41.8%)
CRP (833 participants), mean ± SD 4.31 ± 3.62 mg/L
Traditional CV risk factors
BMI (829 participants), mean ± SD 27.01 ± 4.02
HBP (811 participants), n (%) 400 (49.3%)
High cholesterol (798 participants), n (%) 256 (32.1%)
Smoking habit (836 participants), n (%) 264 (31.6%)
MetS (807 participants), n (%) 180 (22.3%)
T2D (811 participants), n (%) 98 (12.1%)
Therapies
ASA (838 participants), n (%) 320 (38.2%)
CCS (841 participants), n (%) 612 (72.8%)
CCSs low dosage (841 participants), n (%) 504 (60.0%)
MTX (841 participants), n (%) 716 (85.1%)
HCQ (813 participants), n (%) 231 (28.5%)
LEF (841 participants), n (%) 186 (22.1%)
SSZ (841 participants), n (%) 113 (13.4%)
Biologic DMARDs (841 participants), n (%) 517 (61.5%)
TNFi (841 participants), n (%) 308 (36.6%)
Non TNFi (841 participants), n (%) 209 (24.9%)
Participants with missing data, n (%): disease duration, 7 (0.8%); extra-articular
features, 1 (0.1%); radiographic damage, 27 (3.2%); maintenance of remission,
5 (0.6%); CRP, 8 (0.9%); BMI, 12 (1.4%); high cholesterol, 43 (5.1%); HBP, 30
(3.6%); smoking habit, 5 (0.6%); MetS, 34 (4.0%); T2D, 30 (3.6%); ASA, 3 (0.3%);
HCQ, 28 (3.3%)
Abbreviations: RA rheumatoid arthritis, RF rheumatoid factor, ACPA Anti-
citrullinated protein antibodies, CRP mean values of C reactive protein during
the follow-up, SD standard deviation, CV cardiovascular, BMI mean body mass
index during the follow-up, MetS metabolic syndrome, HBP high blood
pressure, T2D type 2 diabetes, ASA acetylsalicylic acid, aspirin, CCSs
corticosteroids, MTX methotrexate, HCQ hydroxychloroquine, SSZ sulfasalazine,
LEF leflunomide, TNFi tumour necrosis factor inhibitor
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Discussion
Although the increased CV risk has been established since
many years in RA, only few prospective studies in this set-
ting have been planned and performed. Thus, we designed a
3-year prospective study, enrolling a large cohort of partici-
pants, in order to provide a real-life estimation of the CV
burden in RA. We reported an increased prevalence and in-
cidence of both subclinical and clinical atherosclerosis in
prospectively followed participants, mainly in the subset
with a duration of disease less than 5 years, suggesting the
role of active inflammatory process. We also showed that
the occurrence of subclinical and clinical atherosclerosis de-
rives from a synergy between both RA-related and trad-
itional CV risk factors, pointing out the need of a strict
management of both systemic inflammation and CV risk
factors to improve the long-term outcome of RA.
In our study, we observed a lower occurrence of
subclinical and clinical atherosclerosis than reported in
available meta-analyses on these topics [3, 4, 10]. How-
ever, our results showed a noteworthy increased preva-
lence and incidence of both subclinical and clinical
atherosclerosis in participants with a duration of disease
less than 5 years. The decreased prevalence of both
subclinical and clinical atherosclerosis observed in our
participants with longer disease duration cannot be at-
tributed to deaths or participants lost to follow-up; due
to the specific design of our study, we analysed only
participants fully completing 3 years of prospective fol-
low-up. Furthermore, these results could suggest that
the increased risk of subclinical and clinical atheroscler-
osis is already present in the early stages of RA [35, 36],
and not only related to the reported accrual CV damage
[3, 4, 10]. In this context, patients with RA could be
more prone to plaque instability and rupture, in addition
to accelerated atherosclerosis [9]. The inflammatory
process could contribute more specifically to more se-
vere acute coronary syndromes and strokes [37], which
may be more strongly associated with the presence and
severity of local or systemic inflammation than with
disease duration [38]. In addition, some reversals of the
vascular damage could be achieved after anti-inflamma-
tory therapies [39, 40], suggesting the long-term im-
provement of CV burden observed in our study.
However, considering the evidence of some conflicting
results concerning the role of duration of disease on ac-
celerated atherosclerosis in RA [41], further specifically
designed studies are necessary to entirely elucidate this
issue of CV burden in early stages of the disease.
Analysing predictive factors of occurrence, we clearly
showed that remission significantly reduced the risk of
both subclinical and clinical atherosclerosis. We ob-
served that participants reaching and maintaining the re-
mission during the follow-up experienced a lesser risk of
having these comorbidities. Our data suggest that the
inflammatory process may strongly contribute in enhan-
cing the CV risk [14, 15, 42] and the remission ought to
be considered the pivotal goal for CV risk management
in patients with RA [43]. In fact, a treat-to-target
intervention, aiming at remission, showed to significantly
reduce the occurrence of clinical and subclinical
atherosclerosis in a clinical trial [16, 44]. As suggested
by our data, the consequent decline of CV burden in RA
could be attributable to this better disease management
[13, 45]. In fact, the delay of diagnosis and therapy of
RA could enhance the clinical atherosclerosis, support-
ing the importance of early recognition and treatment of
these patients [46]. Assessing further predictive factors
among the RA-related CV risk factors, we reported an
association between ACPA positivity and elevated CRP
levels with subclinical atherosclerosis. In fact, patients
affected by a seropositive disease with high inflammatory
burden experience an accelerated atherosclerosis [47].
Our prospective study confirms previous paper reporting
the ACPA positivity as a risk factor for development of
Fig. 1 Prevalence of subclinical and clinical atherosclerosis. Analysing the prevalence according to the duration of the disease, we stratified the
participants based on duration of disease < 5 years or duration of disease > 5 years. In participants with duration of disease < 5 years, we recorded
an increased rate of both subclinical and clinical atherosclerosis when compared with participants with duration of disease
> 5 years. ***p < 0.0001
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atherosclerosis in RA, independently of traditional ones
[48]. It has been also suggested that ACPA could impair
the resolution of inflammation within the atherosclerotic
plaque, enhancing the evolution and destabilisation of
the lesions [19, 49]. In addition, ACPA positivity could
correlate with vascular calcifications in RA, a further
marker of accelerated atherosclerosis [50].
Analysing traditional CV risk factors, we observed that
participants with comorbid T2D were at higher risk of
both subclinical and clinical atherosclerosis. Insulin
Table 2 Regression analyses assessing predictive factors of
subclinical atherosclerosis
Clinical variables OR 95%CI p
Univariate analyses
Age 1.01 0.99–1.02 0.10
Male gender 1.18 0.79–1.76 0.42
RF 1.15 0.81–1.65 0.43
ACPA 1.40 1.01–1.94 0.042
Disease duration 1.00 0.98–1.02 0.99
Extra-articular features 1.31 0.74–1.72 0.56
Radiographic damage 0.85 0.61–1.16 0.30
Joint surgery 1.32 0.83–2.08 0.23
Maintenance of remission 0.65 0.47–0.91 0.014
CRP 1.04 1.02–1.07 0.002
BMI 1.02 0.89–1.08 0.52
HBP 8.79 5.87–13.18 < 0.0001
High cholesterol 2.32 0.89–5.53 0.89
Smoking habit 0.99 0.71–1.40 0.99
MetS 3.99 2.83–5.64 < 0.0001
T2D 3.16 2.04–4.88 < 0.0001
ASA 2.59 0.98–4.13 0.08
CCS 1.36 0.68–2.04 0.78
CCSs low dosage 1.25 0.87–1.78 0.22
MTX 1.67 0.98–2.75 0.08
HCQ 0.62 0.42–1.01 0.09
LEF 0.73 0.49–1.09 0.13
SSZ 0.98 0.61–1.57 0.95
Biologic DMARDs 0.58 0.42–1.01 0.07
TNFi 0.99 0.71–1.37 0.95
Non-TNFi 0.67 0.24–1.02 0.12
Multivariate analysis
Age 1.20 0.99–1.05 0.13
Male gender 1.29 0.55–3.04 0.55
HBP 2.03 1.04–4.14 0.042
T2D 4.50 1.74–11.62 0.002
ACPA 2.36 1.19–4.69 0.014
CRP 1.07 1.03–1.14 0.040
Remission 0.25 0.11–0.56 0.001
Italicised values are statistically significant (p < 0.05)
Abbreviations: RF rheumatoid factor, ACPA Anti-citrullinated protein antibodies,
CRP mean values of C reactive protein during the follow-up, BMI mean body
mass index during the follow-up, MetS metabolic syndrome, HBP high blood
pressure, T2D type 2 diabetes, ASA acetylsalicylic acid, aspirin, CCSs
corticosteroids, MTX methotrexate, HCQ hydroxychloroquine, SSZ sulfasalazine,
LEF leflunomide, TNFi tumour necrosis factor inhibitor
Table 3 Regression analyses assessing predictive factors of
clinical atherosclerosis
Clinical variables OR 95%CI p
Univariate analyses
Age 1.01 0.99–1.03 0.30
Male gender 1.14 0.63–2.08 0.65
RF 1.33 0.77–2.32 0.31
ACPA 0.73 0.45–1.28 0.20
Disease duration 0.99 0.95–1.02 0.58
Extra-articular features 1.67 0.94–2.93 0.08
Radiographic damage 089 0.55–1.43 0.63
Joint surgery 0.82 0.38–1.76 0.61
Maintenance of remission 0.55 0.34–0.91 0.20
CRP 1.02 0.99–1.05 0.14
BMI 1.05 0.99–1.08 0.11
HBP 10.69 5.06–22.59 < 0.0001
High cholesterol 2.47 0.56–5.9 0.18
Smoking habit 0.80 0.47–1.35 0.40
MetS 6.27 3.79–10.37 < 0.0001
T2D 2.64 1.48–4.71 0.001
ASA 1.11 0.78–2.01 0.85
CCS 1.44 0.81 2.56
CCSs low dosage 1.91 0.89–3.46 0.09
MTX 1.31 0.64–2.72 0.45
HCQ 0.61 0.34–1.08 0.09
LEF 0.51 0.25–1.07 0.07
SSZ 0.53 0.23–1.24 0.14
Biologic DMARDs 0.67 0.29–1.36 0.35
TNFi 0.55 0.32–1.01 0.07
Non-TNFi 0.59 0.31–1.02 0.09
Multivariate analysis
Age 1.01 0.99–1.05 0.44
Male gender 0.62 0.22–1.73 0.36
HBP 1.85 0.69–4.91 0.21
T2D 6.21 2.19–17.71 0.001
Remission 0.20 0.09–0.95 0.041
Italicised values are statistically significant (p < 0.05)
Abbreviations: RF rheumatoid factor, ACPA Anti-citrullinated protein antibodies,
CRP mean values of C reactive protein during the follow-up, BMI mean body
mass index during the follow-up, MetS metabolic syndrome, HBP high blood
pressure, T2D type 2 diabetes, ASA acetylsalicylic acid, aspirin, CCSs
corticosteroids, MTX methotrexate, HCQ hydroxychloroquine, SSZ sulfasalazine,
LEF leflunomide, TNFi tumour necrosis factor inhibitor
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resistance and T2D were shown as being highly preva-
lent in RA and to enhance the CV burden [51, 52].
Furthermore, T2D and RA could share pathogenic in-
flammatory pathways suggesting possible common
therapeutic targets [53–55]. We also observed that par-
ticipants with comorbid HBP were associated with en-
hanced risk of subclinical atherosclerosis. In fact, HBP
was reported as being highly prevalent in RA, and it is
considered one of the most important predictor of ath-
erosclerosis in rheumatic diseases [56]. Conversely, in
our analyses, some well-known traditional CV risk fac-
tors were not associated with subclinical and clinical
atherosclerosis, including BMI, cholesterol and smoking
habit. Our study confirms what already reported about
some RA paradoxes in the analysis of CV risk. In fact,
the rheumatoid sarcopenia, altering the body compos-
ition, impairs the predictive role of BMI on atheroscler-
otic disease, and the qualitative changes of lipoproteins
induced by the rheumatoid process cannot be routinely
assessed by the quantitative tests, thus limiting the pre-
dictive role of dyslipidaemia in these participants [57,
58]. Finally, the “smoking paradox” was described in RA
due to an index event bias, since smoking habit is associ-
ated with RA and with its associated comorbidities [59].
The results of this study did not show the predict-
ive role of administered therapies on the main
outcomes. In fact, based on the real-life design of the
study, the therapies were not systematically adminis-
tered, and the choice of medications was left to the
physicians, with the consequent risk of a “confound-
ing by indication” bias, due to the possibility that
more intensive treatment could be administered to
those participants affected by a more aggressive dis-
ease. In this context, the lack of randomised con-
trolled trials, specifically designed to evaluate the
effect of different drugs in controlling the insurgence
of atherosclerotic disease in RA, could impair the
possibility to reach definitive conclusions.
Our study could be affected by different limitations, re-
ducing the external validity of the results and suggesting a
cautious interpretation. Despite providing an insight into
CV risk associated with RA, the lack of a control group
avoided to quantify the relative risk of new-onset subclin-
ical and clinical atherosclerosis when compared with
matched participants from general population. Further-
more, the lack of data regarding aortic atherosclerosis,
thoracic or abdominal aortic aneurysm and angina pec-
toris could be considered a further limitation of the
present work. In addition, the original study design did
not allow to fully ascertain the role of therapeutic strat-
egies on subclinical and clinical atherosclerosis. Further
studies, specifically designed and adequately powered, are
needed to fully elucidate the CV burden in RA and the
best therapeutic strategy of those comorbidities and to
confirm the results of the more recent diagnostic tech-
niques and biomarkers in CV assessment in RA [60–62].
Finally, the management of missing data by listwise dele-
tion, removing all data for an observation that has one or
more missing values, could also be disadvantageous than
imputation methods, such as last observation carried for-
ward. In fact, although we considered of not having inad-
vertently removed a class of participants and that our
sample could be large enough to drop data without
substantial loss of statistical power, the assumptions of
“missing completely at random” could be typically difficult
to support, producing possible biased estimates.
Conclusions
In conclusion, we reported an increased prevalence
and incidence of both subclinical and clinical athero-
sclerosis in prospectively followed participants, mainly
in the subset with a duration of disease less than 5
years. We observed that achievement and mainten-
ance of remission is associated with a reduction of
subclinical and clinical atherosclerosis in prospectively
followed participants. Among traditional CV risk fac-
tors, T2D was significantly associated with both sub-
clinical and clinical atherosclerosis, while about other
traditional CV risk factors the RA-specific paradoxes
may limit the role of tests assessing the lipid profile,
smoking habit and BMI. Taking together, our data
support the need of a multi-expertise management of
RA, counteracting the synergy between the systemic
inflammatory process and the traditional CV risk fac-
tors in reducing the CV burden and, thus, improving
the long-term outcome of patients with RA.
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